Clinical Trial Update: A Study of Herceptin (Trastuzumab) in Combination With Cisplatin/Capecitabine Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastric or Gastro-Esophageal Junction Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial of Herceptin with cisplatin and capecitabine in HER2-positive metastatic gastric or gastroesophageal junction cancer was terminated; results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• CISPLATIN (cisplatin)
• HERCEPTIN (trastuzumab)
• Xeloda (capecitabine)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Gastric Cancer | Phase 3 | Status: TERMINATED | Results posted: 2016-11-28